MDT

100.95

+0.14%↑

138.9

-0.46%↓

VEEV

224.25

+1.77%↑

HQY

87.03

+1.99%↑

NEOG

9.94

+0.91%↑

MDT

100.95

+0.14%↑

138.9

-0.46%↓

VEEV

224.25

+1.77%↑

HQY

87.03

+1.99%↑

NEOG

9.94

+0.91%↑

MDT

100.95

+0.14%↑

138.9

-0.46%↓

VEEV

224.25

+1.77%↑

HQY

87.03

+1.99%↑

NEOG

9.94

+0.91%↑

MDT

100.95

+0.14%↑

138.9

-0.46%↓

VEEV

224.25

+1.77%↑

HQY

87.03

+1.99%↑

NEOG

9.94

+0.91%↑

MDT

100.95

+0.14%↑

138.9

-0.46%↓

VEEV

224.25

+1.77%↑

HQY

87.03

+1.99%↑

NEOG

9.94

+0.91%↑

Kodu・Aktsiate loetelu・Denali Therapeutics Inc

Denali Therapeutics Inc

Avatud

SektorTervishoid

20.48 11.36

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

18.53

Max

20.86

Põhinäitajad
By Trading Economics
Sissetulek	-2.8M -127M
Töötajad	517
EBITDA	-12M -134M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+84.6% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	25. veebr 2026

Turustatistika
By TradingEconomics
Turukapital	563M 2.8B
Eelmine avamishind	9.12
Eelmine sulgemishind	20.48

Uudiste sentiment

By Acuity

26%

74%

71 / 360 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

13.355 / 16.44 Toetus ja vastupanu

Denali Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

21. jaan 2026, 23:49 UTC

Suurimad hinnamuutused turgudel

Karman Space & Defense Shares Rise as 2026 Forecast Tops Analyst Estimates

21. jaan 2026, 21:12 UTC

Suurimad hinnamuutused turgudel

Automaker Stocks Rise After Trump Calls Off European Tariffs

21. jaan 2026, 21:00 UTC

Omandamised, ülevõtmised, äriostud

Deutsche Borse Group to Acquire Allfunds for $6.19 Billion

21. jaan 2026, 20:29 UTC

Suurimad hinnamuutused turgudel

Chip Makers Gain After Trump Calls Off European Tariffs

21. jaan 2026, 20:04 UTC

Suurimad hinnamuutused turgudel

Apparel, Footwear Stocks Rise After Trump Calls Off European Tariffs

21. jaan 2026, 23:48 UTC

Market Talk

Nikkei May Rise as U.S.-Europe Tensions Ease -- Market Talk

21. jaan 2026, 23:34 UTC

Market Talk

Gold Falls Amid Easing U.S.-Europe Tensions Over Greenland -- Market Talk

21. jaan 2026, 22:39 UTC

Tulu

Schwab's Profit Jumps on Surge in Brokerage Activity -- 2nd Update

21. jaan 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

21. jaan 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

21. jaan 2026, 21:35 UTC

Omandamised, ülevõtmised, äriostud

Tesla Stock In Focus as Musk and Ryanair Chief Trade Insults. Should Investors Worry? -- Barrons.com

21. jaan 2026, 21:19 UTC

Tulu

Charles Schwab Earnings Miss Estimates. The Stock Is Rising Anyway. -- Barrons.com

21. jaan 2026, 20:45 UTC

Omandamised, ülevõtmised, äriostud

Deutsche Borse Group to Acquire Allfunds for $6.19B

21. jaan 2026, 20:36 UTC

Market Talk

U.S. Natural Gas Posts Back-to-Back Hefty Gains -- Market Talk

21. jaan 2026, 20:31 UTC

Market Talk

Oil Settles Higher With Support From Heating Fuel -- Market Talk

21. jaan 2026, 20:27 UTC

Omandamised, ülevõtmised, äriostud

Deutsche Boerse Expects Combined Company Will Be Able to Achieve Annual Run Rate Pretax Cost Synergies of About EUR60M

21. jaan 2026, 20:27 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

21. jaan 2026, 20:27 UTC

Market Talk

Was It a 'TACO' Event? -- Market Talk

21. jaan 2026, 20:26 UTC

Omandamised, ülevõtmised, äriostud

Deutsche Boerse Has Received Irrevocable Undertakings in Support of Acquisition in Respect of About 48.9% of Allfunds Issued Share Capital Excluding Treasury Shares

21. jaan 2026, 20:23 UTC

Omandamised, ülevõtmised, äriostud

Deutsche Boerse: Allfunds Stockholders to Receive EUR8.80/Shr, Including Cash, Stock and Permitted Dividend

21. jaan 2026, 20:21 UTC

Omandamised, ülevõtmised, äriostud

Deutsche Boerse: Agreement Values Allfunds at About EUR5.3B

21. jaan 2026, 20:19 UTC

Omandamised, ülevõtmised, äriostud

Deutsche Boerse Group Agrees to Buy Allfunds

21. jaan 2026, 20:08 UTC

Tulu

Prologis Revenue Climbs as Warehouse Demand Rebounds -- Update

21. jaan 2026, 20:03 UTC

Market Talk

Precious Metals Drop After Trump Posts About Greenland Deal -- Market Talk

21. jaan 2026, 19:51 UTC

Market Talk

Treasury Markets React to Trump's Softer Tone About Greenland -- Market Talk

21. jaan 2026, 19:43 UTC

Market Talk

U.S. Ethanol Production Expected to Slip -- Market Talk

21. jaan 2026, 19:31 UTC

Market Talk

Gold Settles at Fresh All-Time High -- Market Talk

21. jaan 2026, 19:24 UTC

Tulu

Johnson & Johnson Tops Earnings Estimates and Issues a Solid Outlook. The Stock Falls. -- Barrons.com

21. jaan 2026, 19:10 UTC

Market Talk

Mexican Inflation Seen Picking Up in Early January -- Market Talk

21. jaan 2026, 18:57 UTC

Market Talk

DAVOS: IBM CEO Krishna Says World Is More Volatile Now -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Denali Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

84.6% tõus

12 kuu keskmine prognoos

Keskmine 32.36 USD 84.6%

Kõrge 40 USD

Madal 25 USD

Põhineb 13 Wall Streeti analüütiku instrumendi Denali Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

13 ratings

Osta

Hoia

Müü

Põhineb 13 analüütiku instrumendi Denali Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

13.355 / 16.44Toetus ja vastupanu

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

All events are bearish.

Sentiment

By Acuity

71 / 360 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.